389 related articles for article (PubMed ID: 19949195)
1. High-potency cannabis and the risk of psychosis.
Di Forti M; Morgan C; Dazzan P; Pariante C; Mondelli V; Marques TR; Handley R; Luzi S; Russo M; Paparelli A; Butt A; Stilo SA; Wiffen B; Powell J; Murray RM
Br J Psychiatry; 2009 Dec; 195(6):488-91. PubMed ID: 19949195
[TBL] [Abstract][Full Text] [Related]
2. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.
Di Forti M; Marconi A; Carra E; Fraietta S; Trotta A; Bonomo M; Bianconi F; Gardner-Sood P; O'Connor J; Russo M; Stilo SA; Marques TR; Mondelli V; Dazzan P; Pariante C; David AS; Gaughran F; Atakan Z; Iyegbe C; Powell J; Morgan C; Lynskey M; Murray RM
Lancet Psychiatry; 2015 Mar; 2(3):233-8. PubMed ID: 26359901
[TBL] [Abstract][Full Text] [Related]
3. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV
Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112
[TBL] [Abstract][Full Text] [Related]
4. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.
Di Forti M; Quattrone D; Freeman TP; Tripoli G; Gayer-Anderson C; Quigley H; Rodriguez V; Jongsma HE; Ferraro L; La Cascia C; La Barbera D; Tarricone I; Berardi D; Szöke A; Arango C; Tortelli A; Velthorst E; Bernardo M; Del-Ben CM; Menezes PR; Selten JP; Jones PB; Kirkbride JB; Rutten BP; de Haan L; Sham PC; van Os J; Lewis CM; Lynskey M; Morgan C; Murray RM;
Lancet Psychiatry; 2019 May; 6(5):427-436. PubMed ID: 30902669
[TBL] [Abstract][Full Text] [Related]
5. What is the mechanism whereby cannabis use increases risk of psychosis?
Luzi S; Morrison PD; Powell J; di Forti M; Murray RM
Neurotox Res; 2008 Oct; 14(2-3):105-12. PubMed ID: 19073418
[TBL] [Abstract][Full Text] [Related]
6. Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?
Freeman TP; Morgan CJ; Hindocha C; Schafer G; Das RK; Curran HV
Addiction; 2014 Oct; 109(10):1686-94. PubMed ID: 24894801
[TBL] [Abstract][Full Text] [Related]
7. Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure.
Colizzi M; McGuire P; Giampietro V; Williams S; Brammer M; Bhattacharyya S
Eur Neuropsychopharmacol; 2018 Jul; 28(7):850-862. PubMed ID: 29935939
[TBL] [Abstract][Full Text] [Related]
8. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.
D'Souza DC; Ranganathan M; Braley G; Gueorguieva R; Zimolo Z; Cooper T; Perry E; Krystal J
Neuropsychopharmacology; 2008 Sep; 33(10):2505-16. PubMed ID: 18185500
[TBL] [Abstract][Full Text] [Related]
9. High potency cannabis is associated with tripled risk of psychosis, study indicates.
Torjesen I
BMJ; 2015 Feb; 350():h939. PubMed ID: 25694180
[No Abstract] [Full Text] [Related]
10. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.
Schoeler T; Petros N; Di Forti M; Klamerus E; Foglia E; Ajnakina O; Gayer-Anderson C; Colizzi M; Quattrone D; Behlke I; Shetty S; McGuire P; David AS; Murray R; Bhattacharyya S
Lancet Psychiatry; 2016 Oct; 3(10):947-953. PubMed ID: 27567467
[TBL] [Abstract][Full Text] [Related]
11. Cannabis-induced psychosis associated with high potency "wax dabs".
Pierre JM; Gandal M; Son M
Schizophr Res; 2016 Apr; 172(1-3):211-2. PubMed ID: 26876313
[TBL] [Abstract][Full Text] [Related]
12. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.
van der Pol P; Liebregts N; Brunt T; van Amsterdam J; de Graaf R; Korf DJ; van den Brink W; van Laar M
Addiction; 2014 Jul; 109(7):1101-9. PubMed ID: 24628797
[TBL] [Abstract][Full Text] [Related]
13. Higher average potency across the United States is associated with progression to first cannabis use disorder symptom.
Arterberry BJ; Treloar Padovano H; Foster KT; Zucker RA; Hicks BM
Drug Alcohol Depend; 2019 Feb; 195():186-192. PubMed ID: 30573162
[TBL] [Abstract][Full Text] [Related]
14. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
van Amsterdam J; Brunt T; van den Brink W
J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
[TBL] [Abstract][Full Text] [Related]
15. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).
Hunault CC; Mensinga TT; Böcker KB; Schipper CM; Kruidenier M; Leenders ME; de Vries I; Meulenbelt J
Psychopharmacology (Berl); 2009 May; 204(1):85-94. PubMed ID: 19099294
[TBL] [Abstract][Full Text] [Related]
16. The THC content of cannabis in Australia: evidence and implications.
Hall W; Swift W
Aust N Z J Public Health; 2000 Oct; 24(5):503-8. PubMed ID: 11109687
[TBL] [Abstract][Full Text] [Related]
17. Cannabis psychosis: examining the evidence for a distinctive psychopathology in a systematic and narrative review.
Baldacchino A; Hughes Z; Kehoe M; Blair H; Teh Y; Windeatt S; Crome IB
Am J Addict; 2012 Nov; 21 Suppl 1():S88-98. PubMed ID: 23786516
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of sex on substance use between first episode psychosis patients and healthy people.
Núñez C; Ochoa S; Huerta-Ramos E; Baños I; Barajas A; Dolz M; Sánchez B; Del Cacho N; ; Usall J
Compr Psychiatry; 2016 Aug; 69():169-78. PubMed ID: 27423358
[TBL] [Abstract][Full Text] [Related]
19. [Cannabis and psychosis].
Curtis L; Rey-Bellet P; Merlo MC
Rev Med Suisse; 2006 Sep; 2(79):2099-100, 2102-3. PubMed ID: 17073176
[TBL] [Abstract][Full Text] [Related]
20. Patterns of delta 8 THC and cannabis uptake in Nebraska: A cannabis prohibition state.
Humeniuk R; Habecker P; Cooper-Ohm S; Bevins RA
Int J Drug Policy; 2024 May; 127():104400. PubMed ID: 38554564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
